Cover ImageSALE
市場調查報告書

登革熱疫苗的全球市場:2017年∼2021年

Global Dengue Vaccine Market 2017-2021

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 586140
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
登革熱疫苗的全球市場:2017年∼2021年 Global Dengue Vaccine Market 2017-2021
出版日期: 2017年11月27日 內容資訊: 英文 78 Pages
簡介

關於登革熱疫苗

埃及斑蚊是革熱病毒(DENV)感染的原因。引起登革熱的病毒,屬於黃病毒科的黃病毒屬。登革熱與流感相似,影響成人、兒童、嬰兒,不過,致死性的案例很少。可是,由於體液儲存,重度的出血,器官的障礙或血漿的遺漏等複數要素,登革出血熱是潛在致命的並發症。科學界推測,DENV在非人靈長類動物中進化,首先在東南亞和非洲,然後傳播到世界其他地區。

Technavio的分析師預測,從2017年到2021年期間,全球登革熱疫苗市場將以15.05%的年複合成長率成長。

本報告提供全球登革熱疫苗市場相關調查分析,市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

第3章 調查方法

第4章 簡介

  • 市場概要

第5章 市場情形

  • 市場概況
  • 市場規模與預測

第6章 波特的五力分析

第7章 開發平台分析

第8章 市場區隔:各終端用戶

  • 政府機關
  • 醫院
  • NGO

第9章 市場區隔:各疫苗類型

  • 純粹弱毒疫苗
  • 不活化疫苗

第10章 地區情形

  • 地區比較
  • 登革熱疫苗市場:南北美洲
  • 登革熱疫苗市場:歐洲、中東、非洲地區
  • 登革熱疫苗市場:亞太地區
  • 市場機會

第11章 決策架構

第12章 成長要素與課題

  • 市場成長要素
  • 市場課題

第13章 市場趨勢

  • 授權合約
  • 意識的高漲
  • 診斷技術的進步
  • 為了排除登革熱的新方法

第14章 供應商情形

第15章 主要供應商分析

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi Pasteur
  • 武田藥品工業
  • 其他有力的供應商

第16章 附錄

  • 簡稱清單
目錄
Product Code: IRTNTR15495

About Dengue Vaccine

The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.

Technavio's analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global dengue vaccine market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Dengue Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • GeneOne Life Sciences
  • Medigen Biologics
  • Panacea Biotec
  • Sun Pharmaceutical

Market driver

  • Rapid growth in disease prevalence
  • For a full, detailed list, view our report

Market challenge

  • Regulatory hurdles in vaccine penetration
  • For a full, detailed list, view our report

Market trend

  • Licensing deals
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION

  • Market outline

PART 05: MARKET LANDSCAPE

  • Market overview
  • Market size and forecast

PART 06: FIVE FORCES ANALYSIS

PART 07: PIPELINE ANALYSIS

PART 08: MARKET SEGMENTATION BY END-USER

  • Government institutions
  • Hospitals
  • NGOs

PART 09: MARKET SEGMENTATION BY VACCINE TYPE

  • Live attenuated vaccines
  • Inactivated vaccines

PART 10: REGIONAL LANDSCAPE

  • Regional comparison
  • Dengue vaccine market in Americas
  • Dengue vaccine market in EMEA
  • Dengue vaccine market in APAC
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Licensing deals
  • Growing awareness
  • Advances in diagnostic techniques
  • Novel approach to eliminate dengue

PART 14: VENDOR LANDSCAPE

PART 15: KEY VENDOR ANALYSIS

  • GlaxoSmithKline
  • Merck Sharp & Dohme
  • Sanofi Pasteur
  • Takeda Pharmaceuticals
  • Other prominent vendors

PART 16: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Forms of dengue
  • Exhibit 02: Transmission cycle of dengue infection
  • Exhibit 03: Global dengue vaccine market: Snapshot
  • Exhibit 04: Global dengue vaccine market: Segmentation
  • Exhibit 05: Global dengue vaccine market 2016-2021 ($ millions)
  • Exhibit 06: Global dengue vaccine market: Opportunity analysis
  • Exhibit 07: Five forces analysis
  • Exhibit 08: Pipeline landscape by development phase
  • Exhibit 09: Key clinical trials
  • Exhibit 10: Global dengue vaccine market share by end-user 2016
  • Exhibit 11: Global dengue vaccine market share by end-user 2021
  • Exhibit 12: Global dengue vaccine market by government institutions 2016-2021 ($ millions)
  • Exhibit 13: Global dengue vaccine market by hospitals 2016-2021 ($ millions)
  • Exhibit 14: Global dengue vaccine market by NGOs 2016-2021 ($ millions)
  • Exhibit 15: Types of dengue vaccine
  • Exhibit 16: Licensing of TV003 and TV005 by NIAID
  • Exhibit 17: Global dengue vaccine market by region 2016-2021
  • Exhibit 18: Regional comparison
  • Exhibit 19: Dengue vaccine market in Americas 2016-2021 ($ millions)
  • Exhibit 20: Dengue vaccine market in Americas: Year over year growth
  • Exhibit 21: Dengue vaccine market in EMEA 2016-2021 ($ millions)
  • Exhibit 22: Dengue vaccine market in EMEA: Year over year growth
  • Exhibit 23: Dengue vaccine market in APAC 2016-2021 ($ millions)
  • Exhibit 24: Dengue vaccine market in APAC: Year over year growth
  • Exhibit 25: Vaccines in global dengue vaccine market
  • Exhibit 26: GlaxoSmithKline: Key highlights
  • Exhibit 27: GlaxoSmithKline: Strength assessment
  • Exhibit 28: GlaxoSmithKline: Strategy assessment
  • Exhibit 29: GlaxoSmithKline: Opportunity assessment
  • Exhibit 30: Merck Sharp & Dohme: Key highlights
  • Exhibit 31: Merck Sharp & Dohme: Strength assessment
  • Exhibit 32: Merck Sharp & Dohme: Strategy assessment
  • Exhibit 33: Merck Sharp & Dohme: Opportunity assessment
  • Exhibit 34: Sanofi Pasteur: Key highlights
  • Exhibit 35: Sanofi Pasteur: Strength assessment
  • Exhibit 36: Sanofi Pasteur: Strategy assessment
  • Exhibit 37: Sanofi Pasteur: Opportunity assessment
  • Exhibit 38: Takeda Pharmaceuticals: Key highlights
  • Exhibit 39: Takeda Pharmaceuticals: Strength assessment
  • Exhibit 40: Takeda Pharmaceuticals: Strategy assessment
  • Exhibit 41: Takeda Pharmaceuticals: Opportunity assessment
Back to Top